Pricing Log in Create free account
Saturday 17 October 2026 Export VRTX’s income statement to Excel — free account

Vertex Pharmaceuticals Incorporated

VRTX Healthcare Biotechnology

Vertex Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $12.0 billion, up 8.90% from fiscal 2024. In the quarter to June 2026, revenue grew 12.5%, EPS grew 7.96% and free cash flow grew 9.25%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years.

499.39 9.36 −1.84%
Market cap
$129.0B
P/E
28.8×
Fwd P/E
25.5×
Dividend yield
—
F-score
8/9
Altman Z
12.06
Beneish M
−2.17
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Vertex Pharmaceuticals Incorporated (VRTX) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
8-K Aug 27, 2026 5.02 Departure or appointment of directors or officers Officer departure
10-Q Jun 30, 2026 P1I2: 82 added · 43 removed · 77 modified
P2I1A: 19 added · 2 removed · 6 modified
8-K Aug 3, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 6, 2026 1.01 Entry into a material definitive agreement; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
8-K May 13, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K May 4, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 28, 2026 5.02 Departure or appointment of directors or officers
8-K Mar 31, 2026 8.01 Other events
10-K Dec 31, 2025 1: 772 added · 167 removed · 157 modified
1A: no comparison — the Item could not be matched reliably
7: 402 added · 79 removed · 86 modified
8-K Feb 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 3, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
10-K Dec 31, 2024

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.